Research desk · RNAC · Nasdaq
RNAC Stock
SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.
Cartesian Therapeutics, Inc. · Pharmaceutical Preparations
Cartesian Therapeutics, Inc. financial statements, chart, and peer compare from SEC filings.
Cartesian Therapeutics, Inc. (RNAC) discovers, develops, or markets pharmaceutical products.
- Market cap
- $302.2M
- P/E
- -5.47
- Op. margin
- -189.24%
- Profit margin
- -111.29%
- FCF margin
- -180.02%
- ROE
- 29.57%
Related Health Care stocks: ABCL stock financials · OCUL stock financials · RXRX stock financials · VRDN stock financials · NKTR stock financials
RNAC financial statements
Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.
RNAC stock peer compare
Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.
Focus chart
Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.
RNAC stock peer headlines
Yahoo Finance RSS for RNAC and the names in Compare.
| Ticker | Date | Headline |
|---|---|---|
| Loading headlines… | ||
RNAC stock price chart
Overlays follow the Compare table.
RNAC stock — research snapshot
Screen strengths and watchouts for RNAC stock from the latest Misprise snapshot.
Strengths
- ROE 29.6% — efficient equity returns.
- EPS CAGR 5Y 49.2% — earnings compounding.
- Debt/equity -0.42 — leverage looks manageable.
- Current ratio 7.48 — liquidity cushion.
Watchouts
- ROA -11.6% — muted asset returns.
- Operating margin -189.2% — thin operating cushion.
- Negative profit margin — earnings quality needs scrutiny.
- Negative FCF margin — cash generation is under pressure.
- Revenue CAGR negative — multi-year top-line contraction.
- Rev CAGR 5Y -52.5%
- Rev CAGR 3Y -84.7%
- EPS CAGR 5Y 49.2%
- EPS CAGR 3Y —
- FCF CAGR 5Y —
- FCF CAGR 3Y 34.2%
RNAC stock FAQs
Short answers for RNAC stock — statements, sector, and how this page is meant to be used.
What is RNAC stock?
Cartesian Therapeutics, Inc. (RNAC) discovers, develops, or markets pharmaceutical products. RNAC stock sits in Health Care (Pharmaceutical Preparations), listed on Nasdaq.
Where can I find Cartesian Therapeutics, Inc. financial statements?
Cartesian Therapeutics, Inc. financial statements — income statement, balance sheet, and cash flow — are on this RNAC stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.
What happened to RNAC stock?
This page is a research snapshot of Cartesian Therapeutics, Inc. (RNAC) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.
Does this page show the RNAC stock price?
The live chart on this RNAC stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.
What sector is RNAC stock in?
Cartesian Therapeutics, Inc. is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.
How do I read RNAC financial statements?
Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.
Where does the RNAC statement data come from?
Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.
Where can I find the RNAC income statement, balance sheet, and cash flow?
On this RNAC stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.
What is the Misprise Score for RNAC stock?
RNAC stock currently scores 0/100 (Watch / incomplete (<60)). Cartesian Therapeutics, Inc. scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.
How is the RNAC comparison winner decided?
Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.
What is the Anomaly Score on this RNAC page?
Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.
What does the green grant dot mean on RNAC stock?
A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.
Is RNAC stock a buy?
No recommendation either way. This RNAC stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell Cartesian Therapeutics, Inc..